Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
Subtype terms (2)
More specific conditions that are subtypes of Substance Withdrawal Syndrome in the MeSH hierarchy.
- Alcohol Withdrawal Delirium
30 drugs (26 approved, 4 experimental)
- Alcohol Withdrawal Seizures
2 drugs approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (12)
Phase 3 trials (25)
Phase 2 trials (12)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (26)
- Pfizer
- Neurocrine Biosciences
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- Arizona State University
- CAMC Health System
- Gelderse Vallei Hospital
- Indiana University
- Santa Barbara Cottage Hospital
- St. Petersburg Bekhterev Research Psychoneurological Institute
- Sorlandet Hospital HF
- University of Nevada, Reno
- University of Toronto
- University of Bologna
- Virginia Commonwealth University
- Wageningen University
- Mayo Clinic
- Deventer Ziekenhuis
- University of California, San Francisco
- University of Colorado, Denver
- University of Vienna
- Catholic University of Sacred Heart, Rome
- University of Colorado
- Los Angeles Clinical Trials
- Universidad de la Frontera
- Centro Medico Nacional La Raza, IMSS
Organization Involved with Phase 3 Indications (16)
- Elite Laboratories, Inc
- The EMMES Corporation
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS)
- Brown University
- University of Kentucky
- University of California, Los Angeles
- University of Cincinnati
- University of Copenhagen
- University of Indonesia
- Vince & Associates
- US WorldMeds
- University of Paris
- Humboldt University
- Los Angeles Treatment Research Center
- Government of France
Organization Involved with Phase 2 Indications (22)
- Lumena Pharmaceuticals
- Shire
- Chiesi
- Cognitive Research Corporation
- Lallemand SAS
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
- University of Pennsylvania
- University of Arizona
- Duke University
- Johns Hopkins University
- Sydney South West Area Health Service
- Thomas Jefferson University
- University of Padova
- Duquesne University
- Mednax Center for Research, Education and Quality
- Medical University of South Carolina
- University of Minnesota
- Q & T Research
- University of New South Wales
- Corella Drug Treatment Service
- MedQualis
- BioXcel Therapeutics Inc
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (6)